PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
-100.00%
Cost reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
100.00%
Growth of 100.00% while RVPH shows flat gross profit. Bruce Berkowitz would examine quality advantage.
100.00%
Margin change of 100.00% while RVPH shows flat margins. Bruce Berkowitz would examine quality advantage.
7.04%
R&D growth while RVPH reduces spending. John Neff would investigate strategic advantage.
-5.63%
G&A reduction while RVPH shows 1.63% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
2.59%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
13.04%
D&A growth while RVPH reduces D&A. John Neff would investigate differences.
-2.44%
EBITDA decline while RVPH shows 9.70% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Operating income decline while RVPH shows 13.36% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Other expenses reduction while RVPH shows 140.48% growth. Joel Greenblatt would examine advantage.
-3.66%
Pre-tax income decline while RVPH shows 18.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while RVPH reduces burden. John Neff would investigate differences.
-10.34%
Net income decline while RVPH shows 18.67% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-10.26%
EPS decline while RVPH shows 28.57% growth. Joel Greenblatt would examine position.
-10.26%
Diluted EPS decline while RVPH shows 28.57% growth. Joel Greenblatt would examine position.
0.08%
Share count reduction exceeding 1.5x RVPH's 11.87%. David Dodd would verify capital allocation.
0.08%
Diluted share reduction exceeding 1.5x RVPH's 11.87%. David Dodd would verify capital allocation.